Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | FASN | P49327 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7190673 | 0.90 | CA12 (0.47) | CA12CA1CA2CA6CA9 | |
| SCHEMBL562162 | 0.80 | CES1 (0.54) | CA12CA1CA2CA6CA9 | |
| SCHEMBL16516134 | 0.79 | CES2 (0.55) | CA12CA1CA2CA6CA9 | |
| SCHEMBL3220949 | 0.75 | CES2 (0.55) | CA12CA1CA2CA6CA9 | |
| SCHEMBL7196195 | 0.72 | CES1 (0.50) | CA12CA1CA2CA6CA9 | |
| SCHEMBL17978693 | 0.72 | CYP2C9 (0.55) | CA12CA1CA2CA6CA9 | |
| SCHEMBL17979123 | 0.72 | CYP2C9 (0.55) | CA12CA1CA2CA6CA9 | |
| SCHEMBL29631326 | 0.72 | CYP2C9 (0.55) | CA12CA1CA2CA6CA9 | |
| SCHEMBL17978820 | 0.72 | CYP2C9 (0.55) | CA12CA1CA2CA6CA9 | |
| SCHEMBL7940799 | 0.71 | CA12 (0.57) | CA12CA1CA2CA6CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244486-A1 | AB Modulating Peptides | ALZYME PTY LTD. (AU) | 2016-08-25 | — | — | US | disclosed |
| US-7803774-B2 | Modulators of β-amyloid peptide aggregation | PRAECIS PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| EP-1870419-A2 | Modulators of beta-amyloid peptide aggregation comprising d-amino acids | Praecis Pharmaceuticals Incorporated (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20070248996-A1 | Modulators of beta-amyloid peptide aggregation comprising D-amino acids | PARAECIS PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1161449-B1 | MODULATORS OF BETA-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS | PRAECIS PHARM INC (US) | 2007-07-04 | — | — | EP | disclosed |
| US-7175828-B2 | peptidic structure, preferably based on beta -amyloid peptide, that is composed entirely of D-amino acids that can bind to natural beta amyloid peptides ( beta -AP), modulate the aggregation of natural beta -AP and/or inhibit the neurotoxicity of natural beta -APs | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060014696-A1 | Modulators of beta-amyloid peptide aggregation comprising D-amino acids | PRAECIS PHARMACEUTICALS, INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-20050288222-A1 | Methods for enhancing the bioavailability of a drug | HAYWARD NEIL J | 2005-12-29 | — | — | US | disclosed |
| EP-1586584-A1 | Modulators of beta-amyloid peptide aggregation comprising D-amino acids | Praecis Pharmaceuticals Incorporated (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-0929574-B1 | MODULATORS OF beta-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS | PRAECIS PHARM INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050137128-A1 | Modulators of ß-amyloid peptide aggregation | PRAECIS PHARMACEUTICALS, INC. (US) | 2005-06-23 | — | — | US | disclosed |
| US-6831066-B2 | Amyloid precursor proteins with improved bioavailability; for treament of Alzheimer's disease | PRAECIS PHARMACEUTICALS INCORPORATED | 2004-12-14 | — | — | US | disclosed |
| US-6689752-B2 | AMINO-TERMINAL MODIFYING GROUPS INCLUDE CYCLIC, HETEROCYCLIC, POLYCYCLIC AND BRANCHED ALKYLS, AND CARBOXY-TERMINAL MODIFYING GROUPS INCLUDE AN AMIDE, AN ALKYL AMIDE, AN ARYL AMIDE OR A HYDROXY; TREATING ALZHEIMER'S DISEASE | PRAECIS PHARMACEUTICALS, INCORPORATED | 2004-02-10 | — | — | US | disclosed |
| US-6610658-B1 | Oligopeptides used as time release agents, for transporting drugs across the blood-brain barrier, medical diagnosis and therapy for amyloidosis such as Alzheimer's disease | PRAECIS PHARMACEUTICALS INC. | 2003-08-26 | — | — | US | disclosed |
| US-6303567-B1 | FOR DIAGNOSIS AND THERAPY OF AMYLOIDOGENIC DISEASES SUCH AS ALZHEIMER'S DISEASE | PRAECIS PHARMACEUTICALS, INC . | 2001-10-16 | — | — | US | disclosed |
| US-6277826-B1 | CONSISTING OF D-LEUCINE, D-PHENYLALANINE AND D-VALINE; PEPTIDE IS MODIFIED AT THE AMINO-TERMINUS, THE CARBOXY-TERMINUS, OR BOTH WITH AN AMIDE OR A HYDROXY GROUP | PRAECIS PHARMACEUTICALS, INC. | 2001-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070248996-A1 | Modulators of beta-amyloid peptide aggregation comprising D-amino acids | APP, IAPP, BACE1 | CA12 2300/4885CA1 1112/4885CA2 2706/4885 |
| US-20060014696-A1 | Modulators of beta-amyloid peptide aggregation comprising D-amino acids | APP, IAPP, BACE1 | CA12 2300/4885CA1 1112/4885CA2 2706/4885 |
| US-20050137128-A1 | Modulators of ß-amyloid peptide aggregation | APP, IAPP, BACE1 | CA12 2760/4885CA1 1557/4885CA2 2575/4885 |
| US-20050288222-A1 | Methods for enhancing the bioavailability of a drug | IAPP, APP, VIP | CA12 2002/4885CA1 1526/4885CA2 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.